triazoles has been researched along with Cardiovascular Diseases in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (37.93) | 29.6817 |
| 2010's | 31 (53.45) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L; Hu, J; Ku, T; Li, G; Liu, Y; Sang, N; Tan, X; Xie, Y; Zhou, M | 1 |
| Desai, RJ; Kim, E; Kim, SC; Lii, J; Neogi, T | 1 |
| Bonnefoi, H; Castiglione, M; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Maibach, R; Neven, P; Rabaglio, M; Regan, MM; Ruepp, B; Sun, Z; Thürlimann, B; Wardley, A | 1 |
| Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB | 1 |
| Bartsch, LA; Castillo-Rodriguez, E; Fernandez-Prado, R; Kanbay, M; Ortiz, A; Perez-Gomez, MV | 1 |
| Gupta, MK; Singh, JA | 1 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Ingle, JN | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Kabbara, WK; Ramadan, WH | 1 |
| Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F | 1 |
| Markun, S | 1 |
| Zechmann, S | 1 |
| Holman, RR; Peterson, ED | 1 |
| Ashcroft, DM; Rutter, MK; Wright, AK | 1 |
| Kumar, HK | 1 |
| Kay, GN | 1 |
| Ferri, E; McKenna, CE; Petosa, C | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ | 1 |
| Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C | 1 |
| Altundag, K | 1 |
| Boyle, B; Cohen, C; DeJesus, E; Elion, R; Frank, I; Moyle, G; Sax, P | 1 |
| Kim, JB; Mahdavi, H; Navab, M; Safarpour, S; Tien, DA | 1 |
| Pfefferkorn, JA | 1 |
| Agarwal, MB | 1 |
| Freeman, JS | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 1 |
| Boudes, P; Viereck, C | 1 |
| Jellinger, PS | 1 |
| Scheen, AJ | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Shapiro, D | 1 |
| Adelman, JU; Lewit, EJ | 1 |
| SICHENEDER, T | 1 |
| Dougherty, RH; Hayden, D; Leder, BZ; Rohrer, JL; Rubin, SD | 1 |
| Burke-Gaffney, A; Callister, ME; Nakamura, H | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Michaud, LB | 1 |
| Bunck, MC; Gooren, LJ; Lips, P; Toorians, AW | 1 |
| Erban, JK | 1 |
| Chlebowski, RT | 1 |
| de la Vega Prieto, MJ; Gaspar, MR; González-Reimers, E; Martínez-Riera, A; Rodríguez, JJ; Santolaria, F; Valls, MR | 1 |
| Lewis, S | 1 |
| Fabian, CJ | 1 |
| Perez, EA | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Wengström, Y | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C | 1 |
| Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B | 1 |
| Coates, A; Mouridsen, H; Thürlimann, B | 1 |
| Ijzerman, AP; Timmerman, H; van Muijlwijk-Koezen, JE | 1 |
| Knobel, M | 1 |
19 review(s) available for triazoles and Cardiovascular Diseases
| Article | Year |
|---|---|
Potential Dangers of Serum Urate-Lowering Therapy.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Oxidative Stress; Polyethylene Glycols; Thioglycolates; Triazoles; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Female; Follow-Up Studies; Fractures, Bone; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain | 2015 |
Bromodomains: Structure, function and pharmacology of inhibition.
Topics: Acetylation; Antineoplastic Agents; Autoimmune Diseases; Azepines; Benzodiazepines; Cardiotonic Agents; Cardiovascular Diseases; Chromatin; Chromatin Assembly and Disassembly; Drug Discovery; Epigenesis, Genetic; Histones; Humans; Models, Molecular; Neoplasms; Transcription Factors; Transcription, Genetic; Triazoles | 2016 |
'Muscle-sparing' statins: preclinical profiles and future clinical use.
Topics: Animals; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Muscular Diseases; Pyrazoles; Pyrimidines; Risk Assessment; Treatment Outcome; Triazoles | 2009 |
Deferasirox: oral, once daily iron chelator--an expert opinion.
Topics: Benzoates; Cardiovascular Diseases; Chelating Agents; Deferasirox; Expert Testimony; Hemosiderosis; Humans; Iron; Liver; Thalassemia; Triazoles | 2010 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Comparative aspects of triptans in treating migraine.
Topics: Carbazoles; Cardiovascular Diseases; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Piperidines; Pyrrolidines; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Triazoles; Tryptamines | 2001 |
Thioredoxin: friend or foe in human disease?
Topics: Cardiovascular Diseases; Dioxanes; Humans; Molecular Structure; Naphthalenes; Neoplasms; Pyridazines; Spiro Compounds; Thioredoxins; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Estrogens; Female; Humans; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Thromboembolism; Triazoles; Triglycerides | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain | 2008 |
The adenosine A3 receptor and its ligands.
Topics: Adenosine; Amino Acid Sequence; Animals; Cardiovascular Diseases; Cloning, Molecular; Flavonoids; Humans; Immune System Diseases; Lung Diseases; Models, Animal; Molecular Sequence Data; Protein Binding; Pyrans; Pyridines; Quinazolines; Receptors, Purinergic; Sequence Alignment; Species Specificity; Triazoles; Xanthines | 2001 |
13 trial(s) available for triazoles and Cardiovascular Diseases
| Article | Year |
|---|---|
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2021 |
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Renal Insufficiency; Retreatment; Symptom Flare Up; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2017 |
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Topics: Aged; Analysis of Variance; Anastrozole; Aromatase Inhibitors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; Homeostasis; Humans; Hypogonadism; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Nitriles; Risk Factors; Testosterone; Triazoles; Vascular Cell Adhesion Molecule-1 | 2005 |
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
Topics: Anastrozole; Androgens; Aromatase Inhibitors; Bone and Bones; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Estradiol; Follicle Stimulating Hormone; Humans; Lipids; Luteinizing Hormone; Nitriles; Ovariectomy; Placebos; Risk Factors; Transsexualism; Triazoles | 2006 |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2007 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Risk Factors; Triazoles | 2008 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2008 |
Trazodone and psychosomatic medicine.
Topics: Adult; Antidepressive Agents; Biliary Tract Diseases; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gastrointestinal Diseases; Genital Diseases, Female; Genital Diseases, Male; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychophysiologic Disorders; Pyridines; Respiratory Tract Diseases; Triazoles; Urologic Diseases | 1973 |
26 other study(ies) available for triazoles and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiac energy metabolism disorder mediated by energy substrate imbalance and mitochondrial damage upon tebuconazole exposure.
Topics: Adenosine Triphosphate; Animals; Cardiovascular Diseases; Energy Metabolism; Humans; Male; Mice; Mice, Inbred C57BL; Triazoles | 2024 |
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; Mortality; Polyethylene Glycols; Practice Patterns, Physicians'; Probenecid; Risk Factors; Thioglycolates; Triazoles; United States; United States Food and Drug Administration; Urate Oxidase | 2021 |
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Middle Aged; Randomized Controlled Trials as Topic; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Xanthine Oxidase; Young Adult | 2019 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
[Sitagliptin in diabetes: Severe side effects are rare].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
[Type 2 diabetes: Cardiovascular long-term safety of sitagliptin demonstrated].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and other 'gliptins'--why prescribe them?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2016 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2017 |
Antiretroviral treatment update from the 17th International AIDS Conference.
Topics: Anti-HIV Agents; Cardiovascular Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
Dyslipidemia and cardiovascular diseases.
Topics: Benzimidazoles; Cardiovascular Diseases; Dyslipidemias; Humans; Lipoproteins, HDL; Niacin; Propionates; Triazoles | 2009 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |
[Insulin shock, electro-, tetrazole, triazole convulsions and the peripheral vascular system].
Topics: Cardiovascular Diseases; Cardiovascular System; Convulsive Therapy; Insulin Coma; Seizures; Sympathomimetics; Tetrazoles; Triazoles | 1957 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Secondary Prevention; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
Clinical significance of homocysteine in elderly hospitalized patients.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Creatinine; Female; Hemoglobins; Homocysteine; Humans; Lymphocyte Count; Male; Neutrophils; Nutritional Status; Predictive Value of Tests; Risk Factors; Serum Albumin; Statistics, Nonparametric; Survival Analysis; Triazoles; Vitamin B 12 | 2006 |
Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Life Expectancy; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2008 |